Literature DB >> 18083373

Surgery and sentinel lymph node biopsy.

Mark B Faries1, Donald L Morton.   

Abstract

In patients with melanoma, surgery is pivotal not only for the primary tumor but also for regional and often distant metastases. The minimally invasive technique of sentinel node (SN) biopsy has become standard for detection of occult regional node metastasis in patients with intermediate-thickness primary melanoma; in these patients it has a central role in determining prognosis and a significant impact on survival when biopsy results are positive. Its role in thin melanoma remains under evaluation. The regional tumor-draining SN also is a useful model for studies of melanoma-induced immunosuppression. Although completion lymphadenectomy remains the standard of care for patients with SN metastasis, results of ongoing phase III trials will indicate whether SN biopsy without further lymph node surgery is adequate therapy for certain patients with minimal regional node disease.

Entities:  

Mesh:

Year:  2007        PMID: 18083373      PMCID: PMC2206736          DOI: 10.1053/j.seminoncol.2007.09.010

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  106 in total

Review 1.  Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma.

Authors:  D L Morton; D W Ollila; E C Hsueh; R Essner; R K Gupta
Journal:  CA Cancer J Clin       Date:  1999 Mar-Apr       Impact factor: 508.702

2.  Intraoperative pathologic evaluation of a breast cancer sentinel lymph node biopsy as a determinant for synchronous axillary lymph node dissection.

Authors:  J M Kane; S B Edge; J S Winston; N Watroba; T C Hurd
Journal:  Ann Surg Oncol       Date:  2001-05       Impact factor: 5.344

3.  Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment.

Authors:  A J Cochran; D L Morton; S Stern; A M Lana; R Essner; D R Wen
Journal:  Mod Pathol       Date:  2001-06       Impact factor: 7.842

4.  Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?

Authors:  K M McMasters; D S Reintgen; M I Ross; S L Wong; J E Gershenwald; D N Krag; R D Noyes; V Viar; P B Cerrito; M J Edwards
Journal:  Ann Surg Oncol       Date:  2001-04       Impact factor: 5.344

5.  Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas.

Authors:  C M Balch; S J Soong; T Smith; M I Ross; M M Urist; C P Karakousis; W J Temple; M C Mihm; R L Barnhill; W R Jewell; H J Wanebo; R Desmond
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

6.  Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy.

Authors:  R L Corsetti; H M Allen; H J Wanebo
Journal:  Ann Surg Oncol       Date:  2000-07       Impact factor: 5.344

Review 7.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

8.  Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase.

Authors:  I Bedrosian; M B Faries; D Guerry; R Elenitsas; L Schuchter; R Mick; F R Spitz; L P Bucky; A Alavi; D E Elder; D L Fraker; B J Czerniecki
Journal:  Ann Surg Oncol       Date:  2000-05       Impact factor: 5.344

9.  Prostaglandins regulate melanoma-induced cytokine production in macrophages.

Authors:  C A Eisengart; J R Mestre; H A Naama; P J Mackrell; D E Rivadeneira; E M Murphy; P P Stapleton; J M Daly
Journal:  Cell Immunol       Date:  2000-09-15       Impact factor: 4.868

10.  Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm.

Authors:  G Cohn-Cedermark; L E Rutqvist; R Andersson; M Breivald; C Ingvar; H Johansson; P E Jönsson; L Krysander; C Lindholm; U Ringborg
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

View more
  7 in total

Review 1.  Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.

Authors:  Sanjay P Bagaria; Mark B Faries; Donald L Morton
Journal:  J Surg Oncol       Date:  2010-06-15       Impact factor: 3.454

Review 2.  Primary Melanoma: from History to Actual Debates.

Authors:  Alessandro A E Testori; Stephanie A Blankenstein; Alexander C J van Akkooi
Journal:  Curr Oncol Rep       Date:  2019-12-19       Impact factor: 5.075

3.  Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.

Authors:  Zhengtao Qin; David J Hall; Michael A Liss; Carl K Hoh; Christopher J Kane; Anne M Wallace; David R Vera
Journal:  J Biomed Opt       Date:  2013-10       Impact factor: 3.170

4.  A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging.

Authors:  Derek K Emerson; Karl K Limmer; David J Hall; Sung-Ho Han; William C Eckelman; Christopher J Kane; Anne M Wallace; David R Vera
Journal:  Radiology       Date:  2012-07-02       Impact factor: 11.105

5.  High-frequency 30-MHz sonography in preoperative assessment of tumor thickness of primary melanoma: usefulness in determination of surgical margin and indication for sentinel lymph node biopsy.

Authors:  Koichi Hayashi; Hiroshi Koga; Hisashi Uhara; Toshiaki Saida
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

6.  Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET.

Authors:  Peter Brader; Kaitlyn Kelly; Sheng Gang; Jatin P Shah; Richard J Wong; Hedvig Hricak; Ronald G Blasberg; Yuman Fong; Ziv Gil
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

7.  Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.

Authors:  Anne M Wallace; Linda K Han; Stephen P Povoski; Kenneth Deck; Schlomo Schneebaum; Nathan C Hall; Carl K Hoh; Karl K Limmer; Helen Krontiras; Thomas G Frazier; Charles Cox; Eli Avisar; Mark Faries; Dennis W King; Lori Christman; David R Vera
Journal:  Ann Surg Oncol       Date:  2013-03-17       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.